Prescriber's Corner
Gemtuzumab Ozogamicin: Back Again
Chris Selby,(1) PharmD, BCOP, Lisa R. Yacko,(2) PharmD, BCPS, and Ashley E. Glode,(3) PharmD, BCOP
(1) Division of Adult Medicine, Texas Tech University Health Sciences Center, Dallas, Texas; (2) Amgen, Aurora, Colorado; (3) University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Clinical Pharmacy, Aurora, Colorado
Authors’ disclosures of conflicts of interest are found at the end of this article.
Ashley E. Glode, PharmD, BCOP, 12850 E. Montview Blvd, Mail Stop C238, Aurora, CO 80045
E-mail: ashley.glode@ucdenver.edu
J Adv Pract Oncol 2019;10(1):68–82 |
https://doi.org/10.6004/jadpro.2019.10.1.6 |
© 2019 Harborside™
ABSTRACT
Abstract
Despite the recent onslaught of approved medications in oncology, acute myeloid leukemia (AML) has been a disease state bereft of pharmaceutical development for decades. The long-standing first-line regimen, 7 + 3, was developed in 1973. A group of four physicians at Roswell Park Memorial Institute built upon prior combinations of daunorubicin and cytarabine to find the optimal combination of 7 days of cytarabine and 3 days of daunorubicin (Lichtman, 2013). This regimen has undergone multiple modifications and patient performance status-based stratifications, but has remained the first-line therapy for AML for the past 45 years. In September 2017, gemtuzumab ozogamicin returned to market and shortly thereafter was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for AML, to be administered in combination with 7 + 3, and as monotherapy for both newly diagnosed and relapsed patients with acute myeloid leukemia (NCCN, 2018; US Food & Drug Administration, 2017). Gemtuzumab ozogamicin continues to be explored in various leukemia settings and is a welcomed addition to the currently available treatment options for AML.
For access to the full length article, please
sign in.
